Polycystic ovary syndrome phenotypes

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, with up to 70% of cases remaining undiagnosed as a result of significant clinical heterogeneity. This review describes in detail the diagnostic criteria for PCOS, analyzes the existing phenotypes of the disease, and also describes the etiopathogenetic significance of insulin resistance (IR) in the development of hyperandrogenism and reproductive disorders. For the choice of treatment tactics, the importance not only of accurate diagnosis of PCOS, but also of determining the clinical phenotype of the disease with a detailed analysis of the morphological structure of the ovaries and an additional study of metabolic parameters, such as body weight and IR index, is emphasized. A differentiated approach to the prescription of insulin sensitizers for various PCOS phenotypes has been substantiated.

Full Text

Restricted Access

About the authors

Oiga A. Pustotina

Academy of Medical Education n.a. F.I. Inozemtsev

Author for correspondence.
Email: pustotina@gmail.com
ORCID iD: 0000-0001-6117-7270

Dr. Sci. (Med.), Professor at the Department of Obstetrics and Gynecology with a Course in Reproductive Medicine

Russian Federation, St. Petersburg

References

  1. Yu O., Christ J.P., Schulze-Rath R., et al. Incidence, prevalence and trends in polycystic ovary syndrome (PCOS) diagnosis: A United States population-based study from 2006-2019. Am J Obstet Gynecol. 2023;14:S0002–9378(23)00241-7. doi: 10.1016/j.ajog.2023.04.010.
  2. Joham A.E., Norman R.J., Stener-Victorin E., et al. Polycystic ovary syndrome. Lancet. Diab Endocrinol. 2022;10:668–80. doi: 10.1016/S2213-8587(22)00163-2.
  3. Tomlinson J.A., Pinkney J.H., Evans P., et al. Screening for diabetes and cardiometabolic disease in women with polycystic ovary syndrome. Br J Diab Vasc Dis. 2013;13(3):115–23.
  4. Teede H.J., Misso M.L., Michael F., et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome Fertil Steril. 2018;10(3):364–269. doi: 10.1016/j.fertnstert.2018.05.004.
  5. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to PCOS. Hum Reprod. 2004;19:41–7. doi: 10.1093/humrep/deh098.
  6. De Leo V., Musacchio M.C., Cappelli V., et al. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016;14(1):38. doi: 10.1186/s12958-016-0173-x.
  7. Wawrzkiewicz-Jałowiecka A., Kowalczyk K., Trybek P., et al. In Search of New Therapeutics-Molecular Aspects of the PCOS Pathophysiology: Genetics, Hormones, Metabolism and Beyond. Int J Mol Sci. 2020;21(19):7054. doi: 10.3390/ijms21197054.
  8. Silva M.S.B., Giacobini P. New insights into anti-Mullerian hormone role in the hypothalamic-pituitary-gonadal axis and neuroendocrine development. Cell Mol Life Sci. 2021;78(1):1–16. doi: 10.1007/s00018-020-03576-x.
  9. Azziz R., Carmina E., Dewailly D., et al., et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456–88. doi: 10.1016/j.fertnstert.2008.06.035.
  10. Quinn M., Shinkai K., Pasch L., et al. Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. Fertil Steril. 2014;101:1129–34. doi: 10.1016/j.fertnstert.2014.01.003.
  11. Ramezani Tehrani F., Behboudi-Gandevani S., Bidhendi Yarandi R., et al. Prevalence of acne vulgaris among women with polycystic ovary syndrome: a systemic review and meta-analysis. Gynecol Endocrinol. 2021;37:392–405. doi: 10.1080/09513590.2020.1859474.
  12. Franks S., Hardy K. Androgen Action in the Ovary. Front Endocrinol. (Lausanne). 2018;9:452. doi: 10.3389/fendo.2018.00452.
  13. O’Reilly M.W., Taylor A.E., Crabtree N.J., et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab. 2014;99:1027–36. doi: 10.1210/jc.2013-3399.
  14. Saadia Z. Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non- Obese Women. Med Arch. 2020;74:289–93. doi: 10.5455/medarh.2020.74.289-293.
  15. Lie Fong S., Laven J.S.E., Duhamel A., Dewailly D. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Mullerian hormone using cluster analysis. Hum Reprod. 2017;32(8):1723–31. doi: 10.1093/humrep/dex226.
  16. Shilpa K., Earlina A., Larysa S. The Clinical Manifestations of Polycystic Ovary Syndrome (PCOS) and The Treatment Options. Eur J Biol Med Sci. Res. 2023;11:57–91.
  17. Kumarapeli V., Seneviratne Rde A., Wijeyaratne C.N., et al. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka. Am J Epidemiol. 2008;168(3):321–28. doi: 10.1093/aje/kwn137.
  18. Joham A.E., Teede H.J., Ranasinha S., et al. Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study. J Womens Health (Larchmt). 2015;24(4):299–307. doi: 10.1089/jwh.2014.5000.
  19. Nisenblat V., Norman R.J. Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diab Obes. 2009;16:224–31. doi: 10.1097/MED.0b013e32832afd4d.
  20. Norman R.J., Morman R., Teede H.J. «Tis but thy name that is my enemy»-the problem with the naming of polycystic ovary syndrome. Fertil Steril. 2023 Mar 27;S0015-0282(23)00237-6. doi: 10.1016/j.fertnstert.2023.03.028.
  21. Christ J.P., Cedars M.I. Current Guidelines for Diagnosing PCOS. Diagnost (Basel). 2023;13(6):1113. doi: 10.3390/diagnostics13061113.
  22. Tosi F., Bonora E., Moghetti P. Insulin resistance in a large cohort of women with polycystic ovary syndrome: A comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Hum Reprod. 2017;32:2515–21. doi: 10.1093/humrep/dex308.
  23. Cassar S., Misso M.L., Hopkins W.G., et al. Insulin resistance in polycystic ovary syndrome: A systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31:2619–31. doi: 10.1093/humrep/dew243.
  24. Lim S.S., Davies M.J., Norman R.J., Moran L.J. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618–37. doi: 10.1093/humupd/dms030.
  25. Ovalle F., Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 2002;77(6):1095–105. doi: 10.1016/s0015-0282(02)03111-4.
  26. Unluhizarci K., Karaca Z., Kelestimur F. Role of insulin and insulin resistance in androgen excess disorders. World J Diab. 2021;12:616–29. doi: 10.4239/wjd.v12.i5.616.
  27. Carlomagno G., Unfer V., Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril. 2011;95:2515–6. doi: 10.1016/j.fertnstert.2011.05.027.
  28. Wallace I.R., McKinley M.C., Bell P.M., Hunter S.J. Sex hormone binding globulin and insulin resistance. Clin Endocrinol (Oxf). 2013;78:321–29. doi: 10.1111/cen.12086.
  29. Unfer V., Carlomagno G., Papaleo E., et al. Hyperinsulinemia Alters Myoinositol to d-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS. Reprod Sci. 2014;21:854–8. doi: 10.1177/1933719113518985.
  30. Heimark D., McAllister J., Larner J. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J. 2014;61:111–17. doi: 10.1507/endocrj.ej13-0423.
  31. Facchinetti F., Dante G., Neri I. The ratio of MI to DCI and its impact in the treatment of polycystic ovary syndrome: experimental and literature evidences. Front Gynecol Endocrinol. 2016;3:103–9.
  32. Lagana A.S., Garzon S., Casarin J., et al. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach. Trends Endocrinol Metab. 2018;29:768–80. doi: 10.1016/j.tem.2018.09.001.
  33. Monastra G., Vazquez-Levin M., Bezerra Espinola M.S., et al. D-chiro-inositol, an aromatase down-modulator, increases androgens and reduces estrogens in male volunteers: a pilot study. Basic Clin Androl. 2021;31:13.
  34. Bremer A.A., Miller W.L. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil Steril. 2008;89(5):1039–48. doi: 10.1016/j.fertnstert.2008.02.091.
  35. Diamanti-Kandarakis E., Papalou O., Kandaraki E.A. The Role of Androgen Excess on Insulin Sensitivity in Women. Front Horm Res. 2019;53:50–64. doi: 10.1159/000494902.
  36. Tuorila K., Ollila M.M., Jarvenlin M.R., et al. Hyperandrogenemia in early adulthood is an independent risk factor for abnormal glucose metabolism in middle age. J Clin Endocrinol Metab. 2021;106(11):e4621–33. doi: 10.1210/clinem/dgab456.
  37. Alviggi C., Conforti A., De Rosa P., et al. The Distribution of Stroma and Antral Follicles Differs between Insulin-Resistance and Hyperandrogenism-Related Polycystic Ovarian Syndrome. Front Endocrinol. (Lausanne). 2017;8:117. doi: 10.3389/fendo.2017.00117.
  38. Moghetti P., Tosi F., Bonin C., et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98:E628–37. doi: 10.1210/jc.2012-3908.
  39. Dai S., Zhang H., Yang F., et al. Effects of IGF-1 on the Three-Dimensional Culture of Ovarian Preantral Follicles and Superovulation Rates in Mice. Biology (Basel). 2022;11(6):833. doi: 10.3390/biology11060833.
  40. Young C.H., Snow B., DeVore S.B., et al. Progesterone stimulates histone citrullination to increase IGFBP1 expression in uterine cells. Reproduct. 2021;162:117–27. doi: 10.1530/REP-21-0132.
  41. Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018;182:27–36. doi: 10.1016/j.jsbmb.2018.04.008.
  42. Unfer V., Dinicola S., Russo M. A PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes? Int J Mol Sci. 2023;24. doi: 10.3390/ijms24076213.
  43. Nordio M., Basciani S., Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: Comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019;23:5512–21. doi: 10.26355/eurrev_201906_18223.
  44. Thalamati S. A comparative study of combination of Myo-inositol and D-chiro-inositol versus Metformin in the management of polycystic ovary syndrome in obese women with infertility. Int J Reprod Contracept Obstet Gynecol. 2019; 8:825–29.
  45. Bevilacqua A., Dragotto J., Giuliani A., Bizzarri M. Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. J Cell Physiol. 2019;234:9387–98. Doi: 10.1002/ jcp.27623.
  46. Bevilacqua A., Dragotto J., Lucarelli M., et al. High Doses of D-Chiro-Inositol Alone Induce a PCO-Like Syndrome and Other Alterations in Mouse Ovaries. Int J Mol Sci. 2021;22:5691. doi: 10.3390/ijms22115691.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig.1. Steroidogenesis in PCOS

Download (252KB)
Indexing metadata
3. Fig.2. Steroidogenesis in IR and compensatory hyperinsulinemia

Download (252KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies